Company / Accounts Receivable
VYNE Therapeutics Inc. Accounts Receivable History
FY2020-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$173.0K
FY2022
5-year range
$173.0K / $7.6M
FY2020-FY2022
Trend
-97.7%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $16M to $173,000 over the past 2 years.
Based on SEC 10-K filings.
$173,000 in FY2022.
Declined from $16M to $173,000 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, accounts receivable decreased 97.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $173.0K | -97.7% |
| FY2021 | $7.6M | -52.1% |
| FY2020 | $15.8M | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026